Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients

Autores: Ornelas Arroyo Sofía, Méndez Sánchez Nahum


Campos-Varela I, et al. Cirrhosis due to hepatitis C virus infection has become the most common indication for liver transplantation, however graft infection is virtually a rule leading to cirrhosis in 10% to 30% of patients in 5 to 7 years following transplantation. There are few high quality studies to guide treatment of HCV after liver transplantation. Combination therapy with interferon plus rivabirin has been associated with end of treatment response rates as high as approximately 50% and sustained virological response rates of over 20 % in some series.1 However the optimal time to begin the antiviral therapy still debatable and its usually based on the fibrosis stage. In this regard Castells evaluated the efficacy and safety of treatment with pegylated interferon and rivabirin in the acute phase of recurrent HCV after liver transplantation, when risk of acute rejection is presumably lower. Treatment with combined therapy yielded a sustained virological response of 34.7%. Although proven safe and effective the limited sample size and comparison with patients who did not receive antiviral therapy precluded identification of patients who might obtain the most benefit from this strategy.

Palabras clave:

2014-02-27   |   279 visitas   |   Evalua este artículo 0 valoraciones

Vol. 13 Núm.2. Marzo-Abril 2014 Pags. 160-162 Ann Hepatol 2014; 13(2)